Vaxart Business Summary

Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company that generates revenue primarily through non-dilutive government contracts and strategic licensing collaborations, most notably with the Biomedical Advanced Research and Development Authority (BARDA) and Dynavax Technologies. The company operates in a single business segment focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform. This platform enables the production of room-temperature stable, needle-free vaccine tablets designed to induce both systemic and mucosal immunity. Vaxart’s primary pipeline targets include COVID-19, norovirus, seasonal influenza, and human papillomavirus (HPV). Within the competitive landscape, Vaxart contends with major vaccine developers such as Moderna, Novavax, and HilleVax, positioning itself as a disruptive alternative by eliminating the cold-chain requirements and injection-related barriers associated with traditional liquid-based vaccines. The company was founded by Dr. Sean Tucker, a recognized expert in mucosal immunology who continues to serve as Chief Scientific Officer. The leadership team is led by CEO Steven Lo, who joined in 2024 with over 25 years of biopharmaceutical experience, including previous chief executive roles at Valitor and Zosano Pharma. Supporting the executive suite are CFO Jeroen Grasman, formerly of AltruBio, and Chief Medical Officer Dr. James Cummings, a veteran of the U.S. Army Medical Research and Development Command. The Board of Directors is chaired by Dr. Michael J. Finney and includes Lead Independent Director W. Mark Watson. Vaxart maintains a robust institutional investor base, with significant holdings from major firms including The Vanguard Group, Marshall Wace LLP, and RA Capital Management.